Table 2 Clinical and productive information of participants.
From: Prevalence and impact of fertility preservation among young women with breast cancer
Variable | patients n (%) (n = 313) |
|---|---|
Stage of diagnosis | |
I | 77 (24.6) |
II | 149 (47.6) |
III | 87 (27.8) |
Grade of pathological | |
1 | 3 (1.0) |
2 | 102 (32.6) |
3 | 187 (59.7) |
Unknow | 21 (6.7) |
Hormone receptor status | |
Triple negative | 43 (13.7) |
Estrogen and/or progesterone and/or HER2 positive | 270 (86.3) |
Surgical method | |
Complete mastectomy | 238 (76.0) |
Breast-conserving surgery | 75 (24.0) |
Chemotherapy | |
Neoadjuvant | 52 (16.6) |
Adjuvant | 226 (72.2) |
Neoadjuvant + Adjuvant | 35 (11.2) |
Radiotherapy | |
Yes | 215 (68.7) |
No | 98 (31.1) |
Prescribed hormone therapy | |
TAM/AI | 97 (31.0) |
GnRHa + TAM/AI | 110 (35.1) |
Ovariectomy + AI | 17 (5.4) |
No | 89 (28.4) |
Family history of breast cancer | |
Yes | 9 (2.9) |
No | 304 (97.1) |
Pregnancy/births | |
Never delivered | 40 (12.8) |
Delivered one child | 157 (50.1) |
Delivered two or more child | 116 (37.1) |
Chemotherapy-induced amenorrhea | |
Yes | 34 (10.9) |
No or not sure | 279 (89.1) |
